Navigation Links
Human clinical study demonstrates superior Neptune Krill Oil NKO(R) pharmacokinetic profile
Date:11/19/2008

       - Marine omega-3 phospholipids in NKO(R) outperform established
           nutraceutical and pharmaceutical omega-3 formulations -

       - Study results used to direct Acasti Pharma's prescription drug
                                  program -

LAVAL, QC, Nov. 19 /PRNewswire-FirstCall/ - Neptune Technologies & Bioressources Inc. ("Neptune") (NASDAQ.NEPT - TSX.V.NTB) is pleased to announce positive results from a human clinical trial conducted in Germany in order to study the pharmacokinetic profile of Neptune Krill Oil NKO(R). The objective of the trial was to evaluate the bioavailability and steady state assessment of NKO(R) in a low physiological daily dose and compare it to well-established nutraceutical and pharmaceutical omega-3 formulations by measuring the levels of the omega-3 fatty acids eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) in plasma and erythrocytes.

The clinical study was conducted under controlled, randomized, double-blind and mono-centric conditions, and comprised of a parallel design with four groups of twelve healthy male volunteers each. One of the four groups received NKO(R) (where EPA and DHA are primarily bound to phospholipids), and the three other groups received either a formulated krill oil-like blend, or concentrated DHA/ EPA ethyl esters (where EPA and DHA are primarily ester bound) or a pharmaceutical grade fish oil (where EPA and DHA are primarily bound to triglycerides).

The trial was designed to compare the acute and long-term bioavailability of the omega-3 fatty acids EPA and DHA of each of the formulations standardized to a low physiological daily dose of 500 mg NKO(R). Concentrations of the omega- 3 fatty acids EPA and DHA were analyzed in plasma and erythrocyte membranes at defined time points of 1 day, 7 days, 28 days, 56 days and 112 days, enabling the measure of accumulation, steady state and bioavailability during the normal lifespan of th
'/>"/>

SOURCE NEPTUNE TECHNOLOGIES & BIORESSOURCES INC.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Expiry of Hart-Scott-Rodino Waiting Period for JUVISTA(R) (Human TGF BETA 3)
2. New Initiative Has Shocking Effect: Thousands of Missourians with Abnormal Chromosome Structures Are Not Human
3. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
4. Human Genome Sciences Announces $40 Million Milestone Payment Related to Albuferon(R) Development
5. Novocell Announces Discovery Linking Key Cancer Cell Signaling Pathways With Proliferation and Self-Renewal of Human Embryonic Stem Cells
6. Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at Thomas Weisel Partners Conference
7. Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at BioCentury-Thomson Financial Investment Conference
8. Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at Bear Stearns Conference
9. Human Pheromone Sciences Enters Into Agreement to Reposition and Promote its Natural Attraction(R) Brand
10. Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at Merrill Lynch Conference
11. Premier Research Appoints Global Head of Human Resources

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/1/2009)... Dr. Kerry Solomon announ... and has launched his redesigned website at www.D... Consulting Group. Dr. Solomon is a proven LASIK,... been professionally recognized for his substantia...gery. He is a member of Trusted LASIK Surgeons, w...
(Date:12/1/2009)..., , PLYMOUTH, Mass., Dec. 1 /PRNewswire/ -... ) announced today results from the company sponso...achandra Medical Center in Chennai, India using th...-reconstructable Critical Limb Ischemia (CLI). Sri...nternational-associated institution based in Chenn...
(Date:12/1/2009)..., , SPRINGFIELD, Ill., Dec. 1 /PRNewswi... is proud to announce that it was recently awarded...Awards event on Nov. 13 in New York City. The CLIO...and innovation in the healthcare advertising indus... the world,s most recognized awards competitions f...
(Date:12/1/2009)..., , CRANBURY, N.J., Dec. 1 /PRNewswire-Fir... PTN ) today announced that the U.S. Patent and Tr...0, titled "Cyclic Natriuretic Peptide Constructs."...f cyclic compounds that bind to natriuretic peptid...lead heart failure drug candidate. ,, "Our natr...
Breaking Biology Technology:Charleston LASIK and Cataract Expert Dr. Kerry Solomon Opens New Practice and Launches DrKerrySolomon.com 2Charleston LASIK and Cataract Expert Dr. Kerry Solomon Opens New Practice and Launches DrKerrySolomon.com 3Charleston LASIK and Cataract Expert Dr. Kerry Solomon Opens New Practice and Launches DrKerrySolomon.com 4Charleston LASIK and Cataract Expert Dr. Kerry Solomon Opens New Practice and Launches DrKerrySolomon.com 5Charleston LASIK and Cataract Expert Dr. Kerry Solomon Opens New Practice and Launches DrKerrySolomon.com 6Harvest Technologies Announces Trial Results in its India Study Using BMAC to Treat Patients With Non-Reconstructable Critical Limb Ischemia 2Harvest Technologies Announces Trial Results in its India Study Using BMAC to Treat Patients With Non-Reconstructable Critical Limb Ischemia 3Prairie Heart Institute of Illinois Wins Two CLIO Healthcare Awards 2Palatin Technologies, Inc. Issued U.S. Patent for Heart Failure Drug Candidate 2Palatin Technologies, Inc. Issued U.S. Patent for Heart Failure Drug Candidate 3
...une 17 Pinnacle Biologics, a private,full-service...ay announced,it has entered into a logistic servic... The agreement, which is scheduled to take effect,... distribution rights in,several countries in Europ...losed., "The agreement with Movianto represents a...
...nt that may lessen the epidemic of diarrhea-relate...cientists in the laboratory of Nobel Laureate Feri...ealth Science Center at Houston have discovered a ...easy-to-take treatment. The results of pre-clinica...e journal Proceedings of the National Academy of ...
...lif., June 16 The Ensign,Group, Inc. (Nasdaq: EN...f,skilled nursing, rehabilitative care services an...its Board of Directors has declared a,quarterly ca...ock, payable,on or before July 31, 2008 to shareho...en a dividend-paying company since 2002, paying an...
Other Biology Technology:Pinnacle Biologics Announces Logistics Services Agreement With the Movianto Group 2Novel compound may treat acute diarrhea 2Novel compound may treat acute diarrhea 3Novel compound may treat acute diarrhea 4Novel compound may treat acute diarrhea 5The Ensign Group Declares Quarterly Dividend 2
(Date:11/30/2009)...ors of The Journal of Experimental Biology are p...re National de la Recherche Scientifique (CNRS) in...ner of this year,s JEB Outstanding Paper Prize. ...ding achievement and is intended to encourage youn...or-in-Chief, and adds that ,we truly appreciate wh...
(Date:11/30/2009)...antage of lower early bird registration rates and ...congress of 2010 at http://www.iofwco-ecceo10.org...of the International Osteoporosis Foundation (IOF)...c Aspects of Osteoporosis and Osteoarthritis (ESCE...orld are expected to attend. The exciting scientif...
(Date:11/30/2009)... , VILNIUS, Lithuania, Nov. 30 /PRNewswire/ ...m ), a provider of high-precision biometric identi...es in the company,s core product line: VeriLook ...gnition and MegaMatcher 3.1 SDK for large-scale ...cation systems (AFIS). Expanded capabilities in Ve...
Breaking Biology News(10 mins):French scientist wins the Journal of Experimental Biology Outstanding Paper Prize 2009 2French scientist wins the Journal of Experimental Biology Outstanding Paper Prize 2009 3French scientist wins the Journal of Experimental Biology Outstanding Paper Prize 2009 4New VeriLook 4.0 for Biometric Facial Recognition and MegaMatcher 3.1 for Multi-biometric Applications Are Now Available 2New VeriLook 4.0 for Biometric Facial Recognition and MegaMatcher 3.1 for Multi-biometric Applications Are Now Available 3St Jude Childrens Research Hospital and UF Proton Therapy Institute to Begin Proton Therapy Clinical Trial 60964 1St Jude Childrens Research Hospital and UF Proton Therapy Institute to Begin Proton Therapy Clinical Trial 60964 2St Jude Childrens Research Hospital and UF Proton Therapy Institute to Begin Proton Therapy Clinical Trial 60964 3St Jude Childrens Research Hospital and UF Proton Therapy Institute to Begin Proton Therapy Clinical Trial 60964 4Yongye International Announces Conference Call to Discuss Third Quarter 2009 Results 14768 1Yongye International Announces Conference Call to Discuss Third Quarter 2009 Results 14768 2Yongye International Announces Conference Call to Discuss Third Quarter 2009 Results 14768 3CEL SCI Collaborators Present Data Suggesting That LEAPS Technology Has Ability to Modify Immune Response 14763 1CEL SCI Collaborators Present Data Suggesting That LEAPS Technology Has Ability to Modify Immune Response 14763 2CEL SCI Collaborators Present Data Suggesting That LEAPS Technology Has Ability to Modify Immune Response 14763 3
...e against neuroAIDS, the nerve damage caused by HI... think and move. As evidence of the progress, rese...ter today received a $7 million grant to confirm t...m HIV-related nerve damage. Driving their approach... against AIDS do not cure neuroAIDS. , As many as ...
...(Germany) and the ESRF have just discovered the wa...ne by studying it with the synchrotron X-rays. Thi...mability of bones. The hierarchical structure of b...out breaking, de-spite being made of essentially r...e published this week in the PNAS online edition. ...
... illness goes hand-in-hand with enlargement of a b...chers at UT Southwestern Medical Center and the Ce.... , The region of the brain called the pulvinar... who carry the gene. , "This might indicate th...ulvinar are more strongly influenced in such indiv...
Other Biology News:Researchers seek to design first treatment for neuroAIDS 2Researchers seek to design first treatment for neuroAIDS 3Researchers seek to design first treatment for neuroAIDS 4Bones at the nanoscale 2Gene linked with mental illness shapes brain region, researchers find 2
Rabbit Anti-pCrosstide Polyclonal Antibody, Horseradish Peroxidase Conjugated from Abcam
Anti-Histone H2B, acetyl (Lys20) Antibody, Unconjugated from Cell Signaling Technology
Congo Red Solution from ScyTek Laboratories
Rabbit Anti-ATGL Polyclonal Antibody, Unconjugated from Cell Signaling Technology
Biology Products: